Sanofi India Limited has informed the Exchange regarding Board meeting held on July 31, 2025.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts less than Nifty Microcap 250 and 3.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi India reported its unaudited Q1 FY2025 (quarter ended June 30, 2025) and H1 FY2025 results on July 31, 2025. Revenue from operations fell to ₹4,063 million in Q1 from ₹4,635 million a year ago, a decline of about 12%. H1 revenue slipped marginally to ₹9,422 million from ₹9,743 million. Despite the revenue dip, profit from continuing operations rose sharply to ₹1,890 million in H1 from ₹1,402 million, a jump of roughly 35%, helped by lower costs and no exceptional charge this year (versus ₹457 million personnel separation cost in H1 FY24). EPS for the quarter stood at ₹30.18. The Board also accepted the retirement of Ms. Renee Amonkar as Whole-time Director and Site Director - Goa effective August 11, 2025, and approved the appointment of Mr. Mahadev Gawade, formerly with Sandoz India, in her place for a three-year term. Separately, the company announced a new promotion and distribution partnership with Emcure Pharmaceuticals for its Oral Anti-diabetic products.
Profitability has improved meaningfully on better cost control and the absence of one-time charges, which should be viewed positively. However, the year-on-year revenue decline and the loss of the in-house OAD business to a distribution model with Emcure may weigh on top-line growth and prompt closer scrutiny of the underlying business trajectory. The director transition appears routine and is unlikely to move the stock.